The 2017 Request for Application (RFA) is now closed.
We are inviting competitive Letters of Intent (LOIs) that outline research with the potential to transform our understanding of NETs and/or lead to improved treatments and diagnostics for patients. LOIs may focus on any type of NET and may propose basic, translational, or clinical cancer research. We welcome multidisciplinary groups combining not only expertise in basic, translational, or clinical research, but also in biotechnology and nanotechnology, or other relevant disciplines. Proposals that cover promising and potentially transferable mechanisms and/or technologies, which have been applied successfully to other areas of cancer research, are highly desirable and will be evaluated based on their level of applicability to NETs.
Some areas of interest include but are not limited to: application of existing or new technologies to study, understand and target NETs – the immune microenvironment, nanotherapies – clinical, correlative, adaptive studies – nuclear medicine, theranostics, imaging – metastasis drivers, biomarkers.
We will award:
At least one 4-year Accelerator award in the amount of $1,200,000 ($300K/year).
At least one 2-year Petersen Investigator award in the amount of $300,000 ($150K/year).
One to three 1-year Pilot Project awards not to exceed $100,000 ($50K-100K/year).
The deadline for submitting a competitive LOI is September 5, 2017.
We are currently not accepting applications for the cell line prize.
Please visit our site in 2018 for an update.
The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Neuroendocrine Tumor Research Foundation therefore wishes to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This challenge requires written documentation, detailed description of each cell line, and sample delivery.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116